Copy Link Print Information

Temuterkib

(Synonyms: LY3214996)
39 Cited Publications
Revisión del cliente

Based on 39 publication(s) in Google Scholar

Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC50 of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

Para uso exclusivo en investigación. No vendemos a pacientes.

  • Pureza : 99.93%
  • No. CAS: 1951483-29-6
  • Fòrmula: C22H27N7O2S
  • Peso molecular:453.56
  • Almacenamiento:
    Powder   -20°C, 3 years , 4°C, 2 years ; In solvent   -80°C, 1 year , -20°C, 6 months
  • Temuterkib Chemical Structure
    Temuterkib Chemical Structure
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
  • Experimental Validation Results for Temuterkib
No. CAS: 1951483-29-6
Tamaño
Precio
Stock
Cantidad
Amount: USD 0.00
Please select quantity
or
or

* Seleccione Cantidad antes de agregar artículos.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Temuterkib:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Encuentre su distribuidor local Your local distributor: Hycultec GmbHHycultec
  • Actividad biológica
  • Chemical Information
  • Solvente y solubilidad
  • Pureza y Documentación
  • Referencias
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Temuterkib

More
Customer Validation & Images
IPWBBio/Physico-chemical AssayIF
  • WB
  • Bio/Physico-chemical Assay
  • WB
  • IF
  • IP
  • IP
  • WB

Ver todos los productos específicos de isoformas ERK

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtener un presupuesto En stock

Other size
Obtener un presupuesto
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Inicie sesiòn
Registrar
Sign in to MedChemExpress
Registrar una cuenta nueva

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Temuterkib Chemical Structure
    Temuterkib Chemical Structure
    1/16
  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Autophagy. 2025 Mar;21(3):565-582. [Abstract]

    Customer Validation
     Western blot analysis of sgCtrl, sgUSP13#1 or sgUSP13#2 A549 cell lysates treated with DMSO or Temuterkib (LY3214996, 10 μM, 24 h) and probed with the indicated antibodies.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Cells were pre-treated with DMSO, 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), or 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM) for 2h, respectively; then Ca2+ mobilization in Fura-2-loaded cells respectively upon FGF19 stimulation were measured and expressed as means ± SEM of 12 independent cells each group.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Subcellular location of NFATc2 after FGF19 treatment: Huh-7 NCSCs were pre-treated with DMSO, BLU9931 (100 nM), 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM), SKF96365 (5 µM), and FK506 (50 nM) for 2h, respectively; then treated with FGF19 (100 ng/ml) for 4h.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Mar 5;11(10):5045-5060. [Abstract]

    Customer Validation
     Subcellular location of NFATc2 after FGF19 treatment: Huh-7 NCSCs were pre-treated with DMSO, BLU9931 (100 nM), 3-NC (20 µM), Temuterkib (LY3214996, 2 µM), 3-NC (20 µM) + Temuterkib (LY3214996, 2 µM), SKF96365 (5 µM), and FK506 (50 nM) for 2h, respectively; then treated with FGF19 (100 ng/ml) for 4h.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Sep 30;5(1):197. [Abstract]

    Customer Validation
     Endogenous and exogenous LSH were respectively immunoprecipitated from A549 and 293T cells after treatment with the MAPK1/2 inhibitor Temuterkib for the indicated time, and then IB assay was carried out to detect the phosphorylated LSH with anti-phosphoserine antibody.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2020 Sep 30;5(1):197. [Abstract]

    Customer Validation
     IP followed by IB assay in PC9 cell lines stably expressing LSH after treatment with the MAPK1/2 inhibitor Temuterkib for the indicated time.

  • 1/16

    Temuterkib purchased from MedChemExpress. Usage Cited in: Cancer Sci. 2019 May;110(5):1746-1759. [Abstract]

    Customer Validation
     Cells are treated with RA in the presence or absence of the Erk1/2 inhibitor LY3214996, phospho-Erk1/2, Erk1/2, phospho-JNK, JNK, phospho-c-Jun, c-Jun, total and cleaved PARP, phospho-STAT3S727, and STAT3 are analyzed.

  • Temuterkib